Amy Li, MD, PhD

Although hematopoietic stem cell transplantation is the only curative treatment for some pediatric leukemia patients, chronic graft-versus-host disease (cGVHD) is a potentially life-threatening immune complication of stem cell transplantation. Li’s research aims to mitigate the effects of cGVHD by enhancing the activity of regulatory T cells (Tregs), which are immunosuppressive T lymphocytes. Specifically, she is studying the effect of a novel class of drugs called thalidomide analogs on Treg survival and function. Li will use genetic screens, cell culture and mouse models to elucidate the mechanisms by which thalidomide analogs alter Treg activity and to determine whether treatment with thalidomide analogs can mitigate cGVHD severity. She hopes that these studies will identify methods to strengthen Treg function and inform novel strategies to improve therapies for cGVHD. Li received her PhD from the Massachusetts Institute of Technology, her MD from Harvard Medical School, Boston, and her BA from Harvard University, Cambridge.